Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
News|Videos|October 2, 2026
PharmTech AI Pulse Check: Episode 2 - Shadow AI, Trade Secrets, the API Race
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Advertisement
Advertisement
In the second episode of PharmTech's new biweekly video series, “PharmTech AI Pulse Check,” host Chris Cole, associate editorial director, PharmTech, sits down with three expert co-hosts—Richard Jaenisch, Open Biopharma Research and Training Institute, Florin Muraru, independent regulatory affairs advisor, and Gourav Pandey, R&D quality lead, Takeda—to unpack three fast-moving flashpoints in pharma AI: data governance, the shift toward API-gated scientific literature, and the limits of AI-content detection.
Related to this article
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
Jaenisch, Muraru, and Pandey join PharmTech's Cole to discuss FDA's generative AI paper, ARPA-H's SURPASS trials, and AI accountability.
PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Advertisement
Advertisement